NewBiotics logo — Turning drug resistance into therapeutic breakthroughs, pion...

NewBiotics

Turning drug resistance into therapeutic breakthroughs, pioneering drug molecules for cancer and infectious diseases since 1997.

Founded 1997 Series E Total: $21.87M Health Care, Health and Wellness

General Information

Company Name NewBiotics
Founded Year 1997
Industries Health Care, Health and Wellness
Funding Stage Series E
Social

BounceWatch is an independent company data service, not affiliated with NewBiotics. To contact NewBiotics, visit newbiotics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About NewBiotics

NewBiotics, a pioneering company in the Health Care industry, has been focusing on turning drug resistance into therapeutic breakthroughs since its establishment in 1997. Their emphasis on the discovery and development of drug molecules that utilize the cycle of drug resistance in both cancer and infectious diseases has garnered attention. Acquired by Celmed Biosciences on June 7, 2004, NewBiotics received a significant $4.57M Series E investment on April 27, 2004. The investment was led by Life Science Partners, AgeChem, and Inglewood Ventures. With their innovative approach and strong financial backing, NewBiotics continues to make strides in the field of therapeutic drug development.

Taxonomy: pharmaceuticals, drug resistance, therapeutics, cancer treatment, infectious diseases, drug discovery, acquisition, medical innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series E $4.57M 3
Inglewood Ventures, GeneChem +1
27 Apr 2004
Series C $11.00M 6
BioVeda Capital, Cheng Xin Technology Development Corp +4
25 Jul 2001
Venture Round $6.30M 1
EQT Life Sciences
04 Apr 2000

NewBiotics Alternatives & Competitors

View All Alternatives
NewBiotics vs

Where novel chemistry and innovative drug design come together to tackle orphan and unmet needs in c...

Grant
3 employees
Health Care, Health and Wellness
NewBiotics vs

Aufbau Holdings develops treatments for vision-threatening eye diseases and systemic cancer through...

Venture round
Biotechnology, Health Care
NewBiotics vs

Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular...

Debt Financing
Biotechnology, Health Care

FAQ About NewBiotics

Turning drug resistance into therapeutic breakthroughs, pioneering drug molecules for cancer and infectious diseases since 1997.
NewBiotics was founded in 1997.
NewBiotics operates in Health Care and Health and Wellness. Its work centres on pharmaceuticals, drug resistance, therapeutics and cancer treatment.
NewBiotics has completed 3 funding rounds, raising a total of $21.87M. The latest funding stage is Series E.
Top alternatives and competitors to NewBiotics include Akanocure Pharmaceuticals, Inc. , Aufbau Holdings, Petra Pharma, Applied Immune Technologies, Ventus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NewBiotics and Akanocure Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NewBiotics, https://bouncewatch.com/company/newbiotics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes